Changing faces - Natural course and treatment of hepatitis C after liver transplantation

Journal of Hepatology

Volumn 40, Issue 4, 2004, Pages 699-701

  Bahr, Matthias J ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANEMIA; CHOLESTATIC HEPATITIS; CHRONIC DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOCOMPETENCE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RIBAVIRIN;

EID: 1642349215     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.01.018     Document Type: Editorial

References (42)

1. Dumortier J., Scoazec J.-Y., Chevallier P., Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 40:2004;669-674.
2. Böker K.H.W., Dalley G., Bahr M.J., Maschek H., Tillmann H.L., Trautwein C., et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 25:1997;203-210.
3. Chazouilleres O., Kim M., Combs C., Ferrell L., Bacchetti P., Roberts J., et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 106:1994;994-999.
4. Gane E.J., Naoumov N.V., Qian K.P., Mondelli M.U., Maertens G., Portmann B.C., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 110:1996;167-177.
5. Wright T.L., Donegan E., Hsu H.H., Ferrell L., Lake J.R., Kim M., et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 103:1992;317-322.
6. Dickson R.C., Caldwell S.H., Ishitani M.B., Lau J.Y., Driscoll C.J., Stevenson W.C., et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 61:1996;701-705.
7. Schluger L.K., Sheiner P.A., Thung S.N., Lau J.Y., Min A., Wolf D.C., et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology. 23:1996;971-976.
8. Gane E.J., Portmann B.C., Naoumov N.V., Smith H.M., Underhill J.A., Donaldson P.T., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 334:1996;815-820.
9. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 32:2000;673-684.
10. Wali M., Harrison R.F., Gow P.J., Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 51:2002;248-252.
11. Burak K.W., Kremers W.K., Batts K.P., Wiesner R.H., Rosen C.B., Razonable R.R., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 8:2002;362-369.
12. Berenguer M., Prieto M., Rayon J.M., Mora J., Pastor M., Ortiz V., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 32:2000;852-858.
13. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 122:2002;889-896.
14. Bahr M.J., Rosenau J., Manns M.P. Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 123:2002;2160. author reply 2160.
15. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 36:2002;202-210.
16. Berenguer M., Wright T.L. Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. Clin Liver Dis. 7:2003;631-650.
17. Bahr M.J., Manns M.P. Recurrent hepatitis C in transplanted patients: more questions than answers. Dig Liver Dis. 35:2003;2-6.
18. Crippin J.S., McCashland T., Terrault N., Sheiner P., Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 8:2002;350-355.
19. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 39:2003;389-396.
20. Thomas R.M., Brems J.J., Guzman-Hartman G., Yong S., Cavaliere P., Van Thiel D.H. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 9:2003;905-915.
21. Singh N., Gayowski T., Wannstedt C.F., Shakil A.O., Wagener M.M., Fung J.J., et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 65:1998;82-86.
22. Sheiner P.A., Boros P., Klion F.M., Thung S.N., Schluger L.K., Lau J.Y., et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 28:1998;831-838.
23. Mazzaferro V., Regalia E., Pulvirenti A., Tagger A., Andreola S., Pasquali M., et al. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Transplant Proc. 29:1997;519-521.
24. Terrault N.A. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl. 9:2003;S95-S100.
25. Wright T.L., Combs C., Kim M., Ferrell L., Bacchetti P., Ascher N., et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology. 20:1994;773-779.
26. Feray C., Samuel D., Gigou M., Paradis V., David M.F., Lemonnier C., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 22:1995;1084-1089.
27. Vargas V., Charco R., Castells L., Esteban R., Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc. 27:1995;1222-1223.
28. Boillot O., Berger F., Rasolofo E., Mion F., Chevallier P., Gille D., et al. Effectiveness of early alpha-interferon therapy for hepatitis C virus infection recurrence after liver transplantation. Transpl Int. 9:(Suppl 1):1996;S202-S203.
29. Singh N., Gayowski T., Wannstedt C.F., Marino I.R., Wagener M.M. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant. 10:1996;348-351.
30. Gane E.J., Lo S.K., Riordan S.M., Portmann B.C., Lau J.Y., Naoumov N.V., et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology. 27:1998;1403-1407.
31. Gane E.J., Tibbs C.J., Ramage J.K., Portmann B.C., Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int. 8:1995;61-64.
32. Cattral M.S., Krajden M., Wanless I.R., Rezig M., Cameron R., Greig P.D., et al. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation. 61:1996;1483-1488.
33. Cattral M.S., Hemming A.W., Wanless I.R., Al Ashgar H., Krajden M., Lilly L., et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation. 67:1999;1277-1280.
34. Saab S., Hu R., Ibrahim A.B., Goldstein L.I., Kunder G., Durazo F., et al. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant. 3:2003;328-333.
35. Bizollon T., Palazzo U., Ducerf C., Chevallier M., Elliott M., Baulieux J., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 26:1997;500-504.
36. De Vera M.E., Smallwood G.A., Rosado K., Davis L., Martinez E., Sharma S., et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation. 71:2001;678-686.
37. Narayanan Menon K.V., Poterucha J.J., El-Amin O.M., Burgart L.J., Kremers W.K., Rosen C.B. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 8:2002;623-629.
38. Shakil A.O., McGuire B., Crippin J., Teperman L., Demetris A.J., Conjeevaram H., et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 36:2002;1253-1258.
39. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., Reed A., Hemming A., Howard R., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 8:2002;1000-1006.
40. Lavezzo B., Franchello A., Smedile A., David E., Barbui A., Torrani M., et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 37:2002;247-252.
41. Bizollon T., Ahmed S.N., Radenne S., Chevallier M., Chevallier P., Parvaz P., et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 52:2003;283-287.
42. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 124:2003;642-650.